Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

MarketWatch Sep 26, 2024, 10:49:00 PM ...

Find the latest Cassava Sciences, Inc. SAVA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

He is +2200 in the latest 2025 U.S. Open odds, the fifth-lowest in the 2025 U.S. Open field. Scottie Scheffler, coming off a victory at the Memorial Tournament, is the +280 U.S. Open favorite.

The 2025 outdoor track and field championships continue today with the women's Heptathlon events beginning at 2:45 p.m. ET/11:45 a.m. PT at Hayward Field in Eugene, Oregon. The men's action begins ...